Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
Reason given: Insufficient participant enrollment
Key facts
- Where
- Atlanta, United StatesSee the site
Where in United States
- Centers for Disease Control and PreventionAtlanta, United StatesNo longer taking part
Trial details
- Who runs it
- Centers for Disease Control and Prevention
- Trial code
- NCT06045923
- Record updated
- 5 May 2026
- Original description
The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV.Read full original descriptionShow less
The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV.
Inclusion: Age ≥18 years; AND; HIV infection with CD4 count < 200 cells/uL; AND; Probable or confirmed mpox (does NOT need to be a new diagnosis); AND; Hospitalized while symptomatic from mpox, for reasons other than (or in addition to) infection prevention and control.
Exclusion: In the judgment of the clinical treating team, has a medical condition or other factor that might affect their ability to participate in the evaluation; Inability of the individual or appropriate proxy to provide informed consent.